Literature DB >> 21448350

Effects of CPG ODN on biological behavior of PANC-1 and expression of TLR9 in pancreatic cancer.

Han-Qing Wu1, Bo Wang, Shi-Kai Zhu, Yuan Tian, Jing-Hui Zhang, He-Shui Wu.   

Abstract

AIM: To determine the expression of toll-like receptor 9 (TLR9) in pancreatic tumor and the effects of cytosine phosphate-guanosine oligodeoxynucleotides 2216 (CPG ODN2216) on biological behavior of pancreatic carcinoma cell line PANC-1 and explore their clinical significance.
METHODS: The immunohistochemistry and Western blot were used to determine the expression of TLR9 protein in pancreatic cancer tissues, and immunofluorescence staining was performed to detect the TLR9 protein expression in pancreatic carcinoma cell line PANC-1. To assess the effects of CPG ODN2216 on the invasive property of Panc-1 cells, in vitro cell adhesion, wound-healing scrape, and invasion and cell colony formation were evaluated.
RESULTS: TLR9 was highly expressed in pancreatic cancer tissues and PANC-1 cells. The percentage of positive cells expressing TLR9 protein in human pancreatic tissues, paracancerous tissues and normal tissues were 73.3%, 33.3% and 20.0%, respectively, and the protein expression level of TLR9 was gradually descending (P < 0.05). In vitro tests in wound-healing scrape, cell adhesion, colony formation and matrigel invasion showed that the adhesion and motility of PANC-1 cells in CPG ODN 2216 treatment group were significantly lower than in the control group (P < 0.05). The cell growth assay showed that the proliferative ability of PANC-1 cells in treatment group was significantly decreased and CPG ODN2216 had an inhibitive effect in the growth of Panc-1 cells in a dose and time-dependent manner (P < 0.05).
CONCLUSION: The gene of TLR9 is correlated with the invasive and metastatic potential of human pancreatic carcinoma, and CPG ODN2216 induces the inhibition of migration and invasion of Panc-1 cells.

Entities:  

Keywords:  Biological behavior; Cytosine phosphate-guanosine oligodeoxynucleotides 2216; Pancreatic cancer; Toll-like receptor 9

Mesh:

Substances:

Year:  2011        PMID: 21448350      PMCID: PMC3057161          DOI: 10.3748/wjg.v17.i8.996

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  27 in total

Review 1.  Toll-like receptors: networking for success.

Authors:  David M Underhill
Journal:  Eur J Immunol       Date:  2003-07       Impact factor: 5.532

2.  A rapid in vitro assay for quantitating the invasive potential of tumor cells.

Authors:  A Albini; Y Iwamoto; H K Kleinman; G R Martin; S A Aaronson; J M Kozlowski; R N McEwan
Journal:  Cancer Res       Date:  1987-06-15       Impact factor: 12.701

3.  Adjuvant chemoradiotherapy and chemotherapy in resectable pancreatic cancer: a randomised controlled trial.

Authors:  J P Neoptolemos; J A Dunn; D D Stocken; J Almond; K Link; H Beger; C Bassi; M Falconi; P Pederzoli; C Dervenis; L Fernandez-Cruz; F Lacaine; A Pap; D Spooner; D J Kerr; H Friess; M W Büchler
Journal:  Lancet       Date:  2001-11-10       Impact factor: 79.321

4.  Activation with CpG-A and CpG-B oligonucleotides reveals two distinct regulatory pathways of type I IFN synthesis in human plasmacytoid dendritic cells.

Authors:  Miren Kerkmann; Simon Rothenfusser; Veit Hornung; Andreas Towarowski; Moritz Wagner; Anja Sarris; Thomas Giese; Stefan Endres; Gunther Hartmann
Journal:  J Immunol       Date:  2003-05-01       Impact factor: 5.422

5.  A combined assay of cell viability and in vitro cytotoxicity with a highly water-soluble tetrazolium salt, neutral red and crystal violet.

Authors:  M Ishiyama; H Tominaga; M Shiga; K Sasamoto; Y Ohkura; K Ueno
Journal:  Biol Pharm Bull       Date:  1996-11       Impact factor: 2.233

Review 6.  Toll-like receptors in the pathogenesis of human disease.

Authors:  Donald N Cook; David S Pisetsky; David A Schwartz
Journal:  Nat Immunol       Date:  2004-10       Impact factor: 25.606

Review 7.  Inflammation and cancer.

Authors:  Lisa M Coussens; Zena Werb
Journal:  Nature       Date:  2002 Dec 19-26       Impact factor: 49.962

Review 8.  Epidemiology and prevention of pancreatic cancer.

Authors:  Albert B Lowenfels; Patrick Maisonneuve
Journal:  Jpn J Clin Oncol       Date:  2004-05       Impact factor: 3.019

9.  Bacterial CpG-DNA and lipopolysaccharides activate Toll-like receptors at distinct cellular compartments.

Authors:  Parviz Ahmad-Nejad; Hans Häcker; Mark Rutz; Stefan Bauer; Ramunas M Vabulas; Hermann Wagner
Journal:  Eur J Immunol       Date:  2002-07       Impact factor: 5.532

10.  Type I interferon-mediated stimulation of T cells by CpG DNA.

Authors:  S Sun; X Zhang; D F Tough; J Sprent
Journal:  J Exp Med       Date:  1998-12-21       Impact factor: 14.307

View more
  12 in total

1.  High toll-like receptor (TLR) 9 expression is associated with better prognosis in surgically treated pancreatic cancer patients.

Authors:  Joni Leppänen; Olli Helminen; Heikki Huhta; Joonas H Kauppila; Joel Isohookana; Kirsi-Maria Haapasaari; Petri Lehenkari; Juha Saarnio; Tuomo J Karttunen
Journal:  Virchows Arch       Date:  2017-02-12       Impact factor: 4.064

2.  Toll-like receptor 9 activation by CpG oligodeoxynucleotide 7909 enhances the radiosensitivity of A549 lung cancer cells via the p53 signaling pathway.

Authors:  Sujuan Yuan; Tiankui Qiao; Xuan Li; Xibing Zhuang; Wei Chen; Xue Chen; Qi Zhang
Journal:  Oncol Lett       Date:  2018-01-31       Impact factor: 2.967

Review 3.  Intervention on toll-like receptors in pancreatic cancer.

Authors:  Juan Vaz; Roland Andersson
Journal:  World J Gastroenterol       Date:  2014-05-21       Impact factor: 5.742

4.  Galectin-4 Reduces Migration and Metastasis Formation of Pancreatic Cancer Cells.

Authors:  Ana I Belo; Astrid M van der Sar; Boris Tefsen; Irma van Die
Journal:  PLoS One       Date:  2013-06-18       Impact factor: 3.240

5.  Impact of CHK2-small interfering RNA on CpG ODN7909-enhanced radiosensitivity in lung cancer A549 cells.

Authors:  Wei Chen; Xiaoqun Liu; Tiankui Qiao; Sujuan Yuan
Journal:  Onco Targets Ther       Date:  2012-12-03       Impact factor: 4.147

6.  The effect of ataxia-telangiectasia mutated kinase-dependent hyperphosphorylation of checkpoint kinase-2 on oligodeoxynucleotide 7909 containing CpG motifs-enhanced sensitivity to X-rays in human lung adenocarcinoma A549 cells.

Authors:  Xiaoqun Liu; Xiangdong Liu; Tiankui Qiao; Wei Chen; Sujuan Yuan
Journal:  Onco Targets Ther       Date:  2015-06-10       Impact factor: 4.147

7.  TGF-β Blockade Reduces Mortality and Metabolic Changes in a Validated Murine Model of Pancreatic Cancer Cachexia.

Authors:  Stephanie H Greco; Lena Tomkötter; Anne-Kristin Vahle; Rae Rokosh; Antonina Avanzi; Syed Kashif Mahmood; Michael Deutsch; Sara Alothman; Dalia Alqunaibit; Atsuo Ochi; Constantinos Zambirinis; Tasnima Mohaimin; Mauricio Rendon; Elliot Levie; Mridul Pansari; Alejandro Torres-Hernandez; Donnele Daley; Rocky Barilla; H Leon Pachter; Daniel Tippens; Hassan Malik; Allal Boutajangout; Thomas Wisniewski; George Miller
Journal:  PLoS One       Date:  2015-07-14       Impact factor: 3.240

8.  Naltrexone Inhibits IL-6 and TNFα Production in Human Immune Cell Subsets following Stimulation with Ligands for Intracellular Toll-Like Receptors.

Authors:  Rachel Cant; Angus G Dalgleish; Rachel L Allen
Journal:  Front Immunol       Date:  2017-07-11       Impact factor: 7.561

Review 9.  Dysregulation of signaling pathways associated with innate antibacterial immunity in patients with pancreatic cancer.

Authors:  Robert Słotwiński; Sylwia Małgorzata Słotwińska
Journal:  Cent Eur J Immunol       Date:  2017-01-24       Impact factor: 2.085

10.  Polymer-Mediated Inhibition of Pro-invasive Nucleic Acid DAMPs and Microvesicles Limits Pancreatic Cancer Metastasis.

Authors:  Ibtehaj Naqvi; Ruwan Gunaratne; Jessica E McDade; Angelo Moreno; Rachel E Rempel; Douglas C Rouse; Silvia Gabriela Herrera; David S Pisetsky; Jaewoo Lee; Rebekah R White; Bruce A Sullenger
Journal:  Mol Ther       Date:  2018-02-23       Impact factor: 12.910

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.